文献速递呼吸道感染

英国成人肺炎链球菌血清型趋势、监测及危险因素(2013-2018)

Pneumococcal serotype trends, surveillance and risk factors in UK adult pneumonia, 2013-18.
PubMed 文献 · Thorax · 2019-10-08

该基于人群的前瞻性队列研究纳入2013年9月至2018年8月两所大学医院收治的2934例社区获得性肺炎成人,其中1075例(36.6%)为肺炎链球菌肺炎。肺炎链球菌肺炎年发病率从32.2/10万升至48.2/10万,主要因PCV13non7血清型(56.9%为血清型3)和非疫苗血清型(NVT)增加;PCV13血清型肺炎更常见于英国肺炎链球菌疫苗接种临床风险组(aOR 1.73,95%CI 1.31-2.28),PPV23血清型肺炎更常见于临床风险组之外(aOR 1.54,95%CI 1.13-2.10)。

要点

  • 肺炎链球菌肺炎年发病率从32.2/10万升至48.2/10万,主要因NVT和血清型3增加。
  • PCV13non7血清型占32.5%(56.9%为血清型3),PPV23non13血清型占40.1%(44.1%为血清型8)。
  • PPV23血清型肺炎更常见于当前临床风险组之外的成人(aOR 1.54,95%CI 1.13-2.10)。

核心结论

  • 肺炎链球菌社区获得性肺炎发病率在2013-2018年间上升,主要由非疫苗血清型和血清型3驱动。
  • PPV23血清型肺炎更可能发生于当前识别的临床风险组之外的成人。

研究设计与样本

  • 基于人群的前瞻性队列研究,纳入2013年9月至2018年8月两所大型大学医院收治的社区获得性肺炎成人。
  • 采用新型24价尿单克隆抗体检测和血培养鉴定肺炎链球菌血清型,并与国家侵袭性肺炎链球菌病数据比较趋势。
  • 通过多因素分析确定疫苗型肺炎(PCV13和PPV23)的风险人群。

主要发现

  • 2934例住院CAP成人中1075例(36.6%)为肺炎链球菌肺炎。
  • 肺炎链球菌肺炎年发病率从32.2/10万升至48.2/10万,PCV13non7血清型年发病率比1.12(95%CI 1.04-1.21),NVT血清型年发病率比1.19(95%CI 1.10-1.28)。
  • PCV13non7血清型见于349例(32.5%)肺炎链球菌肺炎患者,其中56.9%为血清型3;PPV23non13血清型见于431例(40.1%),其中44.1%为血清型8。
  • PCV13血清型肺炎更常见于英国肺炎链球菌疫苗接种临床风险组(aOR 1.73,95%CI 1.31-2.28)。
  • PPV23血清型肺炎更常见于临床风险组之外(aOR 1.54,95%CI 1.13-2.10)。

临床怎么用

  • 在成人肺炎链球菌肺炎评估中关注非疫苗血清型和血清型3的增加趋势。
  • 对临床风险组之外成人保持对PPV23血清型肺炎的警惕。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Changes over the last 5 years (2013-18) in the serotypes implicated in adult pneumococcal pneumonia and the patient groups associated with vaccine-type disease are largely unknown. METHODS: We conducted a population-based prospective cohort study of adults admitted to two large university hospitals with community-acquired pneumonia (CAP) between September 2013 and August 2018. Pneumococcal serotypes were identified using a novel 24-valent urinary monoclonal antibody assay and from blood cultures. Trends in incidence rates were compared against national invasive pneumococcal disease (IPD) data. Persons at risk of vaccine-type pneumonia (pneumococcal conjugate vaccine (PCV)13 and pneumococcal polysaccharide vaccine (PPV)23) were determined from multivariate analyses. FINDINGS: Of 2934 adults hospitalised with CAP, 1075 (36.6%) had pneumococcal pneumonia. The annual incidence of pneumococcal pneumonia increased from 32.2 to 48.2 per 100 000 population (2013-18), predominantly due to increases in PCV13non7-serotype and non-vaccine type (NVT)-serotype pneumonia (annual incidence rate ratio 1.12, 95% CI 1.04 to 1.21 and 1.19, 95% CI 1.10 to 1.28, respectively). Incidence trends were broadly similar to IPD data. PCV13non7 (56.9% serotype 3) and PPV23non13 (44.1% serotype 8) serotypes were identified in 349 (32.5%) and 431 (40.1%) patients with pneumococcal pneumonia, respectively. PCV13-serotype pneumonia (dominated by serotype 3) was more likely in patients in the UK pneumococcal vaccination clinical risk group (adjusted OR (aOR) 1.73, 95% CI 1.31 to 2.28) while PPV23-serotype pneumonia was more likely in patients outside the clinical risk group (aOR 1.54, 95% CI 1.13 to 2.10). INTERPRETATION: The incidence of pneumococcal CAP is increasing, predominantly due to NVT serotypes and serotype 3. PPV23-serotype pneumonia is more likely in adults outside currently identified clinical risk groups.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Pick H, Daniel P, Rodrigo C, et al. Pneumococcal serotype trends, surveillance and risk factors in UK adult pneumonia, 2013-18. Thorax. 2019. PMID: 31594801. doi:10.1136/thoraxjnl-2019-213725

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。